JP2020511468A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511468A5
JP2020511468A5 JP2019550653A JP2019550653A JP2020511468A5 JP 2020511468 A5 JP2020511468 A5 JP 2020511468A5 JP 2019550653 A JP2019550653 A JP 2019550653A JP 2019550653 A JP2019550653 A JP 2019550653A JP 2020511468 A5 JP2020511468 A5 JP 2020511468A5
Authority
JP
Japan
Prior art keywords
disease
fibrosis
syndrome
disorder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511468A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022545 external-priority patent/WO2018170201A1/en
Publication of JP2020511468A publication Critical patent/JP2020511468A/ja
Publication of JP2020511468A5 publication Critical patent/JP2020511468A5/ja
Pending legal-status Critical Current

Links

JP2019550653A 2017-03-16 2018-03-15 Mk2阻害剤の重水素化アナログおよびその使用 Pending JP2020511468A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472022P 2017-03-16 2017-03-16
US62/472,022 2017-03-16
PCT/US2018/022545 WO2018170201A1 (en) 2017-03-16 2018-03-15 Deuterated analogs of mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2020511468A JP2020511468A (ja) 2020-04-16
JP2020511468A5 true JP2020511468A5 (enExample) 2021-04-22

Family

ID=63523341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550653A Pending JP2020511468A (ja) 2017-03-16 2018-03-15 Mk2阻害剤の重水素化アナログおよびその使用

Country Status (4)

Country Link
US (1) US11230551B2 (enExample)
EP (1) EP3596085A4 (enExample)
JP (1) JP2020511468A (enExample)
WO (1) WO2018170201A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201902326XA (en) 2014-09-17 2019-04-29 Celgene Car Llc Mk2 inhibitors and uses thereof
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー 9,10,11,12−テトラヒドロ−8h−[1,4]ジアゼピノ[5’,6’:4,5]チエノ[3,2−f]キノリン−8−オン化合物およびその使用
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Mk2阻害剤の重水素化アナログおよびその使用
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
CN117940433A (zh) * 2021-08-27 2024-04-26 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
AU2023207395A1 (en) 2022-01-14 2024-07-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN115925718A (zh) * 2022-12-27 2023-04-07 瑞石生物医药有限公司 一种四环内酰胺衍生物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101687869A (zh) 2007-07-16 2010-03-31 诺瓦提斯公司 作为mk2抑制剂的四环内酰胺衍生物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
US9457707B2 (en) * 2014-09-15 2016-10-04 Nissan North America, Inc. Vehicle auxiliary lamp unit
SG10201902326XA (en) * 2014-09-17 2019-04-29 Celgene Car Llc Mk2 inhibitors and uses thereof
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Mk2阻害剤の重水素化アナログおよびその使用
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー 9,10,11,12−テトラヒドロ−8h−[1,4]ジアゼピノ[5’,6’:4,5]チエノ[3,2−f]キノリン−8−オン化合物およびその使用
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors

Similar Documents

Publication Publication Date Title
JP2020511468A5 (enExample)
JP2020512315A5 (enExample)
JP2020514361A5 (enExample)
JP2020514360A5 (enExample)
ES2988336T3 (es) Un agente antineoplásico 1-((4-(4-fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiquinolin-7-iloxi)metil)ciclopropanamina, su forma cristalina y sus sales
WO2022171184A1 (zh) 作为sos1抑制剂的杂环化合物
CN111471021B (zh) 取代的二氨基甲酰胺和二氨基甲腈嘧啶,其组合物,和用其治疗的方法
JP2011513485A5 (enExample)
JP2020523390A5 (enExample)
JP2024113019A5 (enExample)
JP2013545812A5 (enExample)
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
JP6830888B2 (ja) Jak阻害剤の硫酸水素塩の結晶形およびその製造方法
PT1735286E (pt) Moduladores de canabinóides à base de tetrahidro-indazol
JP2019524660A5 (enExample)
TW201841910A (zh) 胺吡啶衍生化合物之鹽類、其結晶形及其製備方法
JP6894917B2 (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
JP2007509043A5 (enExample)
ES2817448T3 (es) Compuestos de pirimidina como inhibidores de quinasas
ES2340201T3 (es) Moduladores de hexahidro-ciclooctilpirazol cannabinoides.
CN118510779A (zh) 三环稠杂环类pde3/4双重抑制及其用途
CN116375668A (zh) 一种新型紫杉烷类化合物的制备方法、应用
EP2516420B1 (en) Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
TW200800211A (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
CA2813580A1 (en) Substituted pyridazine carboxamide compounds as kinase inhibitor compounds